AJPH
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


American Journal of Public Health, Vol. 87, Issue 12 2045-2048, Copyright © 1997 by American Public Health Association

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Related articles in AJPH
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tuttle, J
Right arrow Articles by Hadler, S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tuttle, J
Right arrow Articles by Hadler, S
The risk of Guillain-Barré syndrome after tetanus-toxoid-containing vaccines in adults and children in the United States.

J Tuttle, R T Chen, H Rantala, J D Cherry, P H Rhodes and S Hadler

National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.

OBJECTIVES: This study examined whether there is a risk that tetanus-toxoid-containing vaccines could cause Guillain-Barré syndrome and, if so, how large the risk is. METHODS: This study was based on previous active surveillance epidemiological studies of Guillain-Barré syndrome and vaccination history. RESULTS: A background rate of 0.3 cases of Guillain-Barré syndrome per million person-weeks has been estimated. By chance, 2.2 people with the syndrome would have received tetanus-toxoid-containing vaccine within the 6 weeks before onset, yet only 1 person had done so. Data on children show similar results. CONCLUSIONS: If an association exists, it must be extremely rare and not of public health significance.


Related articles in AJPH:

Of floors and ceilings--defining, assuring, and communicating vaccine safety.
R F Breiman and J A Zanca
AJPH 1997 87: 1919-1920. [PDF]  



This article has been cited by other articles:


Home page
Postgrad. Med. J.Home page
U. Seneviratne
Guillain-Barre syndrome
Postgrad. Med. J., December 1, 2000; 76(902): 774 - 782.
[Abstract] [Full Text]


Home page
NEJMHome page
A. H. Ropper and M. Victor
Influenza Vaccination and the Guillain-Barre Syndrome
N. Engl. J. Med., December 17, 1998; 339(25): 1845 - 1846.
[Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American Public Health Association